135 related articles for article (PubMed ID: 25880407)
1. Does the target dose of neurohormonal blockade matter for outcome in Systolic heart failure in octogenarians?
Barywani SB; Ergatoudes C; Schaufelberger M; Petzold M; Fu ML
Int J Cardiol; 2015; 187():666-72. PubMed ID: 25880407
[TBL] [Abstract][Full Text] [Related]
2. Treatment with Optimal Dose Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Has a Positive Effect on Long-Term Survival in Older Individuals (Aged >70 Years) and Octogenarians with Systolic Heart Failure.
Sargento L; Simões AV; Longo S; Lousada N; Dos Reis RP
Drugs Aging; 2016 Sep; 33(9):675-83. PubMed ID: 27568454
[TBL] [Abstract][Full Text] [Related]
3. Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis.
Turgeon RD; Kolber MR; Loewen P; Ellis U; McCormack JP
PLoS One; 2019; 14(2):e0212907. PubMed ID: 30817783
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of heart rate in elderly with systolic heart failure and concomitant atrial fibrillation.
Barywani S; Petzold M
Scand Cardiovasc J; 2017 Aug; 51(4):190-196. PubMed ID: 28393567
[TBL] [Abstract][Full Text] [Related]
5. Nurse-led titration of angiotensin converting enzyme inhibitors, beta-adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fraction.
Driscoll A; Currey J; Tonkin A; Krum H
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD009889. PubMed ID: 26689943
[TBL] [Abstract][Full Text] [Related]
6. Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry.
Peri-Okonny PA; Mi X; Khariton Y; Patel KK; Thomas L; Fonarow GC; Sharma PP; Duffy CI; Albert NM; Butler J; Hernandez AF; McCague K; Williams FB; DeVore AD; Patterson JH; Spertus JA
JACC Heart Fail; 2019 Apr; 7(4):350-358. PubMed ID: 30738978
[TBL] [Abstract][Full Text] [Related]
7. Titration of medications and outcomes in multi-ethnic heart failure cohorts (with reduced ejection fraction) from Singapore and New Zealand.
Teng TK; Tay WT; Ouwerkerk W; Tromp J; Richards AM; Gamble G; Greene SJ; Yiu KH; Poppe K; Ling LH; Lund M; Sim D; Devlin G; Loh SY; Troughton R; Ren QW; Jaufeerally F; Lee SGS; Tan RS; Soon DKN; Leong G; Ong HY; Yeo DPS; Lam CSP; Doughty RN
ESC Heart Fail; 2023 Apr; 10(2):1280-1293. PubMed ID: 36722315
[TBL] [Abstract][Full Text] [Related]
8. Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease.
Fröhlich H; Nelges C; Täger T; Schwenger V; Cebola R; Schnorbach J; Goode KM; Kazmi S; Katus HA; Cleland JG; Clark AL; Frankenstein L
Am Heart J; 2016 Aug; 178():28-36. PubMed ID: 27502849
[TBL] [Abstract][Full Text] [Related]
9. Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study.
Santema BT; Ouwerkerk W; Tromp J; Sama IE; Ravera A; Regitz-Zagrosek V; Hillege H; Samani NJ; Zannad F; Dickstein K; Lang CC; Cleland JG; Ter Maaten JM; Metra M; Anker SD; van der Harst P; Ng LL; van der Meer P; van Veldhuisen DJ; Meyer S; Lam CSP; ; Voors AA
Lancet; 2019 Oct; 394(10205):1254-1263. PubMed ID: 31447116
[TBL] [Abstract][Full Text] [Related]
10. A Modern History RAAS Inhibition and Beta Blockade for Heart Failure to Underscore the Non-equivalency of ACEIs and ARBs.
Hyman DA; Siebert VR; Birnbaum GD; Alam M; Birnbaum Y
Cardiovasc Drugs Ther; 2020 Apr; 34(2):215-221. PubMed ID: 32219664
[TBL] [Abstract][Full Text] [Related]
11. The treatment gap in patients with chronic systolic heart failure: a systematic review of evidence-based prescribing in practice.
Chin KL; Skiba M; Tonkin A; Reid CM; Liew D; Krum H; Hopper I
Heart Fail Rev; 2016 Nov; 21(6):675-697. PubMed ID: 27465132
[TBL] [Abstract][Full Text] [Related]
12. Is target dose of beta-blocker more important than achieved heart rate or heart rate change in patients with systolic chronic heart failure?
Porapakkham P; Porapakkham P; Krum H
Cardiovasc Ther; 2010 Apr; 28(2):93-100. PubMed ID: 20398098
[TBL] [Abstract][Full Text] [Related]
13. Role of Guideline Directed Medical Therapy Doses and Optimization in Patients Hospitalized With Decompensated Systolic Heart Failure.
Grewal D; Partow-Navid R; Garcia D; Coney J; Fraser G; Stoletniy L; Sakr A; Parwani P; Abramov D
Am J Cardiol; 2021 Jul; 151():64-69. PubMed ID: 34167690
[TBL] [Abstract][Full Text] [Related]
14. Treatment with higher dosages of heart failure medication is associated with improved outcome following cardiac resynchronization therapy.
Schmidt S; Hürlimann D; Starck CT; Hindricks G; Lüscher TF; Ruschitzka F; Steffel J
Eur Heart J; 2014 Apr; 35(16):1051-60. PubMed ID: 24371079
[TBL] [Abstract][Full Text] [Related]
15. Relation of dosing of the renin-angiotensin system inhibitors after cardiac resynchronization therapy to long-term prognosis.
Mantziari L; Guha K; Khalique Z; McDonagh T; Sharma R
Am J Cardiol; 2012 Jun; 109(11):1619-25. PubMed ID: 22465318
[TBL] [Abstract][Full Text] [Related]
16. Characteristics Associated with Upper-Range Doses of Beta-Blockers and Angiotensin-Renin Inhibitors in Reduced Ejection Fraction.
Itzhaki Ben Zadok O; Murninkas D; Iakobishvili Z; Jino H; Yohananov E; Birkenfeld S; Hasdai D
Isr Med Assoc J; 2020 Jul; 22(7):441-445. PubMed ID: 33236570
[TBL] [Abstract][Full Text] [Related]
17. Association between mortality and persistent use of beta blockers and angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and coronary artery disease.
Allen LaPointe NM; Zhou Y; Stafford JA; Hernandez AF; Kramer JM; Anstrom KJ
Am J Cardiol; 2009 Jun; 103(11):1518-24. PubMed ID: 19463509
[TBL] [Abstract][Full Text] [Related]
18. Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF.
Heywood JT; Fonarow GC; Yancy CW; Albert NM; Curtis AB; Gheorghiade M; Inge PJ; McBride ML; Mehra MR; O'Connor CM; Reynolds D; Walsh MN
Circ Heart Fail; 2010 Sep; 3(5):596-605. PubMed ID: 20634483
[TBL] [Abstract][Full Text] [Related]
19. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study.
Krum H; Shi H; Pitt B; McMurray J; Swedberg K; van Veldhuisen DJ; Vincent J; Pocock S; Zannad F;
Circ Heart Fail; 2013 Jul; 6(4):711-8. PubMed ID: 23625945
[TBL] [Abstract][Full Text] [Related]
20. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system.
Toh S; Reichman ME; Houstoun M; Ross Southworth M; Ding X; Hernandez AF; Levenson M; Li L; McCloskey C; Shoaibi A; Wu E; Zornberg G; Hennessy S
Arch Intern Med; 2012 Nov; 172(20):1582-9. PubMed ID: 23147456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
